ORAGENICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ORAGENICS, INC. (OGEN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.93 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.20, a 150.00% increase year-over-year.
- ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $0.48.
- ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $0.93, a 93.75% increase from fiscal 2024.
- ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.48, a 90.61% decline from fiscal 2023.
- ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.11, a 74.78% decline from fiscal 2022.
- ORAGENICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $20.26, a 1905.94% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.93 10-K · filed 2026-03-16 | ||||
| 2024-12-31 | $0.48 10-K · filed 2025-03-14 | ||||
| 2024-09-30 | $0.48 10-Q · filed 2024-11-13 | ||||
| 2023-12-31 | $5.11 10-K · filed 2024-03-29 | ||||
| 2022-12-31 | $20.26 10-K · filed 2023-04-17 | ||||
| 2022-09-30 | $0.34 10-Q/A · filed 2023-04-14 | ||||
| 2022-06-30 | $0.32 10-Q/A · filed 2023-04-14 | ||||
| 2021-12-31 | $1.01 10-K/A · filed 2022-07-29 | ||||
| 2021-09-30 | $1.19 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $1.20 10-Q · filed 2021-08-16 | ||||
| 2021-03-31 | $1.20 10-Q · filed 2021-05-03 | ||||
| 2020-12-31 | $0.50 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $0.50 10-Q · filed 2020-11-10 | ||||
| 2020-06-30 | $0.48 10-Q · filed 2020-08-14 | ||||
| 2020-03-31 | $0.48 10-Q · filed 2020-05-15 | ||||
| 2019-12-31 | $0.49 10-K · filed 2021-03-01 | ||||
| 2018-12-31 | $0.79 10-K · filed 2020-03-04 | $0.80 10-K · filed 2019-03-29 | |||
| 2017-12-31 | $3.70 10-K · filed 2019-03-29 | ||||
| 2016-12-31 | $6.90 10-K · filed 2018-02-16 | $0.69 10-K · filed 2017-02-27 | |||
| 2015-12-31 | $1.31 10-K · filed 2017-02-27 | ||||
| 2014-12-31 | $1.65 10-K · filed 2016-03-30 | ||||
| 2013-12-31 | $3.13 10-K · filed 2015-02-27 | ||||
| 2012-12-31 | $1.20 10-K · filed 2014-02-28 | ||||
| 2011-12-31 | $3.50 10-K · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |